Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Esophageal NeoplasmsEsophageal Diseases1 moreThis is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303...
Malignant Neoplasm of Digestive SystemThis study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive...
Digestive System NeoplasmsThe purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 with standard adjuvant therapy in subjects with surgically resected digestive system neoplasms.
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma...
CarcinomaIntrahepatic Cholangiocarcinoma3 moreThis is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma.
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors
Advanced Digestive System TumorThis is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to advanced gastric cancer, esophagogastric junction adenocarcinoma, and advanced pancreatic cancer.
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
Gastroesophageal Junction (GEJ) AdenocarcinomaThe main purpose of this study is to evaluate safety, tolerability and the efficacy of Q-1802 plus SOC compared with SOC. .Pharmacokinetics (PK) ,Pharmacodynamics (PD) of Q-1802 and the immunogenicity profile of Q-1802 will be evaluated as well.
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Colorectal CancerEsophagus Cancer3 moreThis is a single-arm clinical trial that will evaluate the feasibility of a chemotherapy regimen adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Invasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma Stage IV13 moreThe purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
ImmunotherapyGastric Cancer3 moreimmunotherapy,gastric cancer,rectal cancer,biomark
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Digestive CancerMetastatic Colorectal Cancer3 moreTargeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of determine the optimal dose adapted for each patient, in the future.